Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 16th Preview)
-
Obesity GLP-1 competition shifts to liver and safety surveillance
Eli Lilly said its oral obesity drug Foundayo met the main goal of a cardiovascular outcomes study in people with diabetes, showing no greater risk of heart attacks and other cardiovascular events than long-acting insulin. The company also reported no greater liver harm, with it hinting at possible reductions in death risk that will require confirmation. Separately, newly disclosed FDA documents show regulators asked Lilly to evaluate liver risk and unexpected serious cardiovascular events in ongoing trials as a condition of approval. The request centers on safety monitoring in the Achieve-4 outcomes trial and submission timelines in coming months. Lilly’s diabetes filing strategy is designed to extend the commercial battle with Novo Nordisk’s GLP-1 franchise. Together, the efficacy readout and the FDA’s liver-focused follow-up indicate that “cardiometabolic benefit” is no longer the only hurdle—ongoing safety evidence will shape labeling and uptake in both obesity and diabetes.
-
Roche reopens Elevidys path toward European approval
Roche announced a new global Phase 3 trial for Duchenne muscular dystrophy gene therapy Elevidys as it tries again for European approval after prior negative European Medicines Agency feedback. The follow-up study will enroll about 100 early ambulatory boys and randomize them to Elevidys or placebo over 72 weeks. The trial’s primary endpoint focuses on meaningful change in “time to rise,” an ability measure that Roche says is an important predictor of disease progression. The update comes after earlier testing in Europe failed to show a meaningful motor function benefit, and after Elevidys faced setbacks including restrictions in the U.S. tied to safety controversies. For Sarepta-developed therapy, the new trial underscores how regulators can drive new evidence requirements even after initial approvals. It also signals that Roche intends to generate resubmission-ready data rather than pursue incremental changes to existing submissions.
-
Revolution Medicines’ daraxonrasib swings trial-level momentum and taps capital markets
Revolution Medicines reported Phase 3 results for daraxonrasib (RMC-6236), a RAS-targeting inhibitor in metastatic pancreatic ductal adenocarcinoma, showing longer progression-free survival and overall survival versus standard chemotherapy in RAS-variant groups. The company reported a median overall survival of 13.2 months on daraxonrasib compared with 6.7 months on chemotherapy, with a generally manageable safety profile. In a near-term follow-on to the clinical readout, the company also priced a $1.5 billion follow-on stock offering and issued convertible senior notes, part of what is described as the largest follow-on in biopharma history. The financing arrived just days after investors reacted to the top-line Phase 3 data. The pairing of survival data with rapid access to public capital highlights how quickly oncology winners can reprice risk perception and move into commercialization and additional development with less dilution.
-
Cochrane verdict reignites the anti-amyloid Alzheimer’s drug debate
A sweeping Cochrane review concluded that anti-amyloid antibody drugs in Alzheimer’s disease produce “no meaningful difference” for patients with mild cognitive impairment or mild dementia. The analysis compiles evidence across randomized controlled trials and directly challenges the clinical benefit narrative that has supported years of drug development. The backlash is immediate in both scientific and regulatory discussions, as the findings collide with prior perceptions that amyloid targeting could modify disease progression. The renewed debate also comes alongside the FDA revisiting related peptide frameworks, adding pressure to the agency and sponsors around evidence standards. For the Alzheimer’s pipeline, the key message is that independent syntheses are increasingly shaping expectations for meaningful clinical outcomes—not just biomarkers or surrogate endpoints.
-
MeiraGTx buys back failed J&J eye gene therapy, while Storm funds a new sarcoma trial
MeiraGTx agreed to buy back full rights to bota-vec, an eye gene therapy previously backed by Johnson & Johnson after a Phase 3 failure in X-linked retinitis pigmentosa. The deal brings the asset back to MeiraGTx for $25 million upfront, positioning it for future strategy changes despite last year’s setback. Meanwhile, Storm Therapeutics raised $56 million in a Pfizer-backed Series C and launched a Phase 2 trial in sarcoma patients. The combination of MeiraGTx’s rights reset and Storm’s new clinical start reflects two distinct funding-and-portfolio moves: reclaiming failed assets for rework versus pushing new candidates forward with fresh capital. Together, the moves show how investors and sponsors manage risk in gene therapy and oncology—either by renegotiating control after clinical failures or accelerating early development with targeted trial plans.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.